Castle Biosciences Reports Second Quarter 2025 Results
Provided By GlobeNewswire
Last update: Aug 4, 2025
Delivered Q2 2025 revenue of $86 million
Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024
Read more at globenewswire.com
